Korea's Hanlim, Daewoong and Pacific Pharmas Prepare Launch For Modified Actonel
This article was originally published in PharmAsia News
SEOUL - South Korean local pharmas Hanlim Pharm, Daewoong Pharmaceutical and Pacific Pharma are gearing up to sell an incrementally modified version of Actonel (risendronate), which was originally developed by Sanofi-Aventis and has been sold in Korea by local firm Handok Pharmaceuticals
You may also be interested in...
Handok, which is partially owned by Sanofi, will sell Roche’s Madopar for Parkinson’s disease in Korea.
SEOUL - MSD Korea, Merck's South Korea branch, will sell a combination antihypertensive in South Korea in partnership with Hanmi Pharmaceutical, marking the first case in South Korea of a multinational company co-marketing a drug developed in part by a South Korean drug manufacturer
FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.